Riky Rebecha1, Yulistiani2,3
1Master of Clinical Pharmacy Program, 2Clinical Pharmacy Department,
Faculty of Pharmacy Airlangga University, Surabaya, Indonesia,
3Clinical Pharmacy Division, Airlangga Teaching Hospital, Surabaya, Indonesia
Coronary heart disease (CHD) mostly caused by atherosclerotic myocardium damage, disrupting coronary blood flow. In 2012, World Health Organization recorded 17.5 million deaths caused by cardiovascular disease or 31% of 56.5 million worldwide mortality. Indonesian Sample Registration System Survey in 2014 showed that CHD was the most common etiology of mortality in all spectrum of ages, following stroke, around 12.9%. CHD classified into 3 groups, unstable angina (UA), non-ST elevation segment myocardial infarction (NSTEMI), and ST elevation segment myocardial infarction (STEMI). The management of CHD consists of analgesics, antithrombotic (antiplatelet and anticoagulant), antiangina and reperfusion therapy. Aspirin and clopidogrel is the most common antiplatelet used with Percutaneous Coronary Intervention (PCI). Newly approved by FDA, Vorapaxar, is an antiplatelet in Protease-Activated Receptor-1 (PARs) class. This paper review biopharmaceutical aspects of drugs for CHD therapy. This review showed that Vorapaxar in CHD was able to decreasing mortality risk due to cardiovascular or ischemic, but in return increasing mild or heavy bleeding risk, include intracranial bleeding.
Keywords: Coronary heart disease, antiplatelet, Vorapaxar, PAR